<DOC>
	<DOCNO>NCT01311752</DOCNO>
	<brief_summary>This study Multicentre cohort study inclusion throughout full duration study . The primary objective study human papillomavirus relate genital pathology HIV positive woman . The secondary objective : 1 . To study characteristic HPV infection relate disease context long term HAART HIV infection ; 2 . To study characteristic atypical cell uncertain significance detect Pap smear , whose prevalence dramatically increase last year ; 3 . To describe cervical cancer observe cohort 4 . To study evolution recurrent high-grade lesion surgery 5 . To describe evolution vaginal lesion develop hysterectomy high-grade lesion ; 6 . To describe specific aspect surgery treatment cervical lesion accord specific localization endocervix HIV-positive woman ; 7 . To study situ T cell HPV specific response cervical lesion relationship virological clinical parameter , host immune status natural history lesion ; 8 . To initiate prospective study anal HPV infection related disease among woman infect HIV . 9 . To initiate study therapeutic and/or prophylactic HPV vaccine context immunosuppression high rate HPV infection ;</brief_summary>
	<brief_title>Study Human Papillomavirus Related Genital Pathology Among HIV Positive Women</brief_title>
	<detailed_description>Data collect evaluate : - Analysis prognostic factor ( CD4 , antiviral therapy ) cervical lesion , use Cox model . - Estimation rate Incidence high grade lesion , recurrence surgical treatment use Kaplan Meier test . - Logistic regression analysis study factor associate complete excision surgical treatment . - SIR ( standardised incidence rate ) evaluation cervical cancer Study procedures Annual follow-up case normal Pap smear , biannual follow-up case cervical lesion . Surgical management High grade lesion .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>woman &gt; 18 year old attending outpatient gynecology consultation HIV positive write informed consent social security unaffiliated social healthy security french system</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>human papillomavirus</keyword>
	<keyword>follow</keyword>
</DOC>